GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line [The Motley Fool]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: The Motley Fool
GlaxoSmithKline Reportedly Trying Again to Sell Antibiotics Line The divestment of its cephalosporin products could bring in several hundred million dollars. GlaxoSmithKline ( NYSE:GSK ) is hanging a "for sale" sign on a group of its antibiotics, according to an article published by Bloomberg. The article, citing "people familiar with the matter," states that the big drugmaker is working with financial advisors to find a buyer for its line of cephalosporins, a type of antibiotics, in a move that could put several hundred million dollars into the company's coffers. Glaxo and its advisors are testing the waters for such a sale, Bloomberg wrote, making preliminary inquiries of interest. Early targets are peer pharmaceutical companies active in the antibiotics segment, as well as investment funds. The company's portfolio of cephalosporins includes the drugs Zinna and Fortum, which collectively bring in roughly $200 million in annual revenue. Glaxo unsuccessfully attempted to sell this l
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
- GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]Seeking Alpha
- New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV DiseaseBusiness Wire
- GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV SeasonsBusiness Wire
GSK
Sec Filings
- 11/14/24 - Form 6-K
- 11/13/24 - Form 6-K
- 11/12/24 - Form SC
- GSK's page on the SEC website